{
    "nct_id": "NCT04675294",
    "official_title": "A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)",
    "inclusion_criteria": "* Patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC) that is PD-L1 positive (CPS > 1) and who have not received prior systemic therapy for their advanced disease.\n* Adequate bone marrow function.\n* Adequate renal and liver function.\n* Adequate ECOG performance status.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.\n* History of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Prior treatment with any anti-CD47 or anti-SIRPÎ± agent.\n* Prior treatment with anti-PD-1 or PD-L1.",
    "miscellaneous_criteria": ""
}